SM04554

Wnt signalling is central to hair-follicle cycling, so a topical modulator is a rational laboratory target. Rational is not the same as clinically proven.

Proposed activation of Wnt/beta-catenin signalling in the follicle, promoting follicle proliferation. The trial protocol itself flags theoretical pathway-related risks.

Key Distinction: An investigational or unapproved compound has no approved indication, and a proposed mechanism is not a demonstrated clinical effect.

Phase 1 and Phase 2 trials were registered and completed. Therapept did not identify an active later-stage registration or an approved product at review.

Peer-reviewed efficacy results from the Phase 2 programme. Current development status. Long-term safety of Wnt modulation in skin.

Publication span: 2019

What Has Actually Been Studied

• Topical SM04554 0.15% and 0.25% in male androgenetic alopecia (Phase 2 protocol) (ClinicalTrials.gov, 2019) — Phase 2 randomised, double-blind, vehicle-controlled trial (protocol record).

Preparation and Handling

Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.

United States Regulatory Status

Investigational

• No approved product in Drugs@FDA as of this review.
• Registered Phase 2 study NCT03742518 evaluated 0.15% and 0.25% topical solution against vehicle in men with androgenetic alopecia.
• The development programme's later status is not established by the registry records reviewed here. Absence of an active registration is not evidence of discontinuation.
• Wnt pathway modulation is the proposed mechanism, and the trial protocol itself flags theoretical pathway-related risks. That is a mechanistic concern, not an observed human safety finding.